StemCell Therapy

What is a Veterinarian?

A veterinarian specializes in the diagnosis, treatment, and prevention of illnesses and injuries in animals. Veterinarians provide medical care to a wide range of animals, including pets, livestock, zoo animals, and wildlife. They perform physical examinations, conduct diagnostic tests such as bloodwork and imaging, prescribe medications, administer vaccines, and perform surgical procedures to treat injuries or illnesses. Veterinarians also offer preventive care services, such as vaccinations, parasite control, and dental care, to help animals maintain optimal health and well-being.

In addition to clinical practice, veterinarians may also work in research, academia, public health, or regulatory agencies, contributing to advancements in veterinary medicine, animal welfare, and public health initiatives.

The workplace of a veterinarian can vary depending on their specialization and the nature of their practice. Many veterinarians work in clinical settings such as animal hospitals, veterinary clinics, or private practices, where they provide medical care to companion animals, livestock, or exotic pets. In these environments, veterinarians typically interact directly with clients and patients, performing physical examinations, diagnosing illnesses or injuries, prescribing medications, and conducting surgical procedures as needed. They may also collaborate with veterinary technicians, assistants, and other staff members to deliver comprehensive care and support services to animals and their owners.

Some veterinarians specialize in specific areas of veterinary medicine, such as equine medicine, exotic animal medicine, or public health, which may influence their workplace environment. Equine veterinarians, for example, may spend a significant amount of time traveling to farms, stables, or racetracks to provide medical care to horses. Exotic animal veterinarians may work in zoos, aquariums, or wildlife rehabilitation centers, caring for a diverse range of species in specialized facilities. Public health veterinarians may work for government agencies, research institutions, or international organizations, focusing on disease surveillance, food safety, or environmental health initiatives.

Link:
What does a veterinarian do? - CareerExplorer

6 in 10 pet owners surveyed in the UK, Austria and Denmark believe their pets should have access to the same healthcare treatment options as humans  Vet Candy

Read the original post:
6 in 10 pet owners surveyed in the UK, Austria and Denmark believe their pets should have access to the same healthcare treatment options as humans -...

He took up running rather than take diabetes medication. It worked  South China Morning Post

See the original post here:
He took up running rather than take diabetes medication. It worked - South China Morning Post

The immune system has many components:

Antigens Innate Immunity are any substance that the immune system can recognize and that can thus stimulate an immune response.

Cells are the smallest unit of a living organism, composed of a nucleus and cytoplasm surrounded by a membrane.

Chemotaxis is the process of by which a chemical substance attracts cells to a particular site.

Helper T cells are white blood cells that help B cells produce antibodies against foreign antigens, help killer T cells become active, and stimulate macrophages, enabling them to ingest infected or abnormal cells more efficiently.

Histocompatibility (literally, compatibility of tissue) is determined by human leukocyte antigens (self-identification molecules). Histocompatibility is used to determine whether a transplanted tissue or organ will be accepted by the recipient.

Human leukocyte antigens (HLA) are a group of identification molecules located on the surface of all cells in a combination that is almost unique for each person, thereby enabling the body to distinguish self from nonself. This group of identification molecules is also called the major histocompatibility complex.

An immune complex is an antibody attached to an antigen.

An immune response is the reaction of the immune system to an antigen.

Immunoglobulin is another name for antibody.

Interleukin is a type of messenger (cytokine) secreted by some white blood cells to affect other white blood cells.

Killer (cytotoxic) T cells are T cells that attach to infected cells and cancer cells and kill them.

Leukocyte is another name for a white blood cell, such as a monocyte, a neutrophil, an eosinophil, a basophil, or a lymphocyte (a B cell or T cell).

Major histocompatibility complex (MHC) is a synonym for human leukocyte antigens.

Mast cells are cells in tissues that release histamine and other substances involved in inflammatory and allergic reactions.

A molecule is a group of atoms chemically combined to form a unique substance.

Natural killer cells are a type of white blood cell that can recognize and kill abnormal cells, such as certain infected cells and cancer cells, without having to first learn that the cells are abnormal.

Phagocytes are a type of cell that ingests and kills or destroys invading microorganisms, other cells, and cell fragments. Phagocytes include neutrophils and macrophages.

Phagocytosis is the process of a cell engulfing and ingesting an invading microorganism, another cell, or a cell fragment.

A receptor is a molecule on a cells surface or inside the cell that can identify specific molecules, which fit precisely in itas a key fits in its lock.

Regulatory (suppressor) T cells are white blood cells that help end an immune response.

See original here:
Overview of the Immune System - The Merck Manuals

SALT LAKE CITY, March 15, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including (ALS) and multiple sclerosis (MS), today reported the publication of “Protein Corona Composition of Gold Nanocatalysts” in the journal ACS Pharmacology & Translational Science, a journal of the American Chemical Society that publishes innovative and impactful research with translational relevance across a broad spectrum of biological sciences.

The rest is here:
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA).

View post:
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.

Excerpt from:
Nuvectis Pharma to Present at the 36th Annual Roth Conference

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders’ equity requirements, through May 20, 2024. The Company is considering all available options that may enable it to timely evidence compliance with the continued listing criteria and maintain its listing on Nasdaq; however, there can be no assurance that the Company will be able to do so.

See the article here:
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

Company Announcement

See the original post here:
Genmab Announces Initiation of Share Buy-Back Program

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES

Originally posted here:
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million

Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET

Read this article:
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ET

Continued here:
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Bankruptcy Court for the Southern District of Texas (the “Court”), in connection with the bankruptcy proceedings of Sorrento Therapeutics, Inc. (“Sorrento”), Scilex’s former controlling stockholder, approved the settlement and mutual release agreement (the “Definitive Settlement Agreement”) between Scilex’s wholly owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex Pharma”), and Sorrento, on the one hand, and Virpax Pharmaceuticals, Inc. (“Virpax”), on the other hand. The Definitive Settlement Agreement relates to the term sheet previously announced by Scilex on February 26, 2024, regarding a mutual release and settlement agreement between Scilex Pharma, Sorrento and Virpax in respect of the action (the “Action”) filed by Scilex Pharma and Sorrento (together, the “Plaintiffs”) against Anthony Mack, former President of Scilex Pharma and Virpax, a company founded and then headed by Mr. Mack. Pursuant to the Definitive Settlement Agreement, Virpax is obligated to make the following payments to the Company: (i) $3.5 million by March 18, 2024 (the “Initial Payment”); (ii) $2.5 million by July 1, 2024 (the “Second Payment”); and (iii) to the extent any of the following drug candidates are ever sold, royalty payments of (a) 6% of annual Net Sales (as defined in the Definitive Settlement Agreement) of Epoladerm; (b) 6% of annual Net Sales of Probudur; and (c) 6% of annual Net Sales of Envelta. Such royalty payments will end upon the later of (i) expiration of the last-to-expire valid patent claim of Virpax or its licensor covering the manufacture, use or sale of such product in such country; and (ii) expiration of any period of regulatory exclusivity for such product in such country.

Excerpt from:
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement...

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer.

Read the rest here:
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it received Halal Certification of its commercial product ZTlido, indicating that ZTlido has undergone rigorous assessment to determine that it is permissible or acceptable in accordance with Islamic standards. The Halal certification was issued under the authority of Circle H International, Inc. (“Circle H”) and offers the Company the opportunity to provide ZTlido to Islamic markets globally. This announcement supports the global expansion strategy for Scilex, which Scilex anticipates will include a presence in the Middle East and North Africa (MENA) region with an initial priority focus on the UAE and Saudi Arabia.

Continued here:
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Read more:
Sanofi: Information concerning the total number of voting rights and shares - February 2024

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps

See more here:
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Link:
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, announces today its intention to broaden its market reach through a recently filed application for listing on the OTCQB® Venture Market (the "OTCQB") in the United States. Listing on the OTCQB is subject to approval of the OTC Markets Group.

See the original post:
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”), one notifying the Company (the “MVLS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “Market Value Standard”), and the other notifying the Company (the “MVPHS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below the minimum of $15 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Standard”).

Read the original post:
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares